

Publikationen

OA Priv. Doz. Dr.

Thomas-Matthias Scherzer

1.

Low Vitamin D Levels Do Not Predict Hyperglycemia in Elderly Endurance Athletes (but in Controls).

Haslacher H, Nistler S, Batmyagmar D, Ponocny-Seliger E, Perkmann T, **Scherzer TM**, Kundi M, Endler G, Ratzinger F, Pilger A, Wagner OF, Winker R.

PLoS One. 2016 Jun 15;11(6):e0157695.

2.

rs6295 [C]-Allele Protects Against Depressive Mood in Elderly Endurance Athletes.

Haslacher H, Michlmayr M, Batmyagmar D, Perkmann T, Ponocny-Seliger E, Scheichenberger V, **Scherzer TM**, Nistler S, Pilger A, Dal-Bianco P, Lehrner J, Pezawas L, Wagner OF, Winker R.

J Sport Exerc Psychol. 2015 Dec;37(6):637-45.

3.

Renal tubular acidosis is highly prevalent in critically ill patients.

Brunner R, Drolz A, **Scherzer TM**, Stauffer K, Fuhrmann V, Zauner C, Holzinger U, Schneeweiß B.

Crit Care. 2015 Apr 6;19:148.

4.

A double-blind, randomized clinical study to determine the efficacy of benzocaine 10% on histamine-induced pruritus and UVB-light induced slight sunburn pain.

Bauer M, Schwameis R, **Scherzer T**, Lang-Zwosta I, Nishino K, Zeitlinger M.

J Dermatolog Treat. 2015;26(4):367-72.

5.

Review article: genetic factors that modify the outcome of viral hepatitis.

Stättermayer AF, **Scherzer T**, Beinhardt S, Rutter K, Hofer H, Ferenci P.

Aliment Pharmacol Ther. 2014 May;39(10):1059-70.

6.

Successful anti-viral treatment improves survival of patients with advanced liver disease due to chronic hepatitis C.

Rutter K, Stättermayer AF, Beinhardt S, **Scherzer TM**, Steindl-Munda P, Trauner M, Ferenci P, Hofer H.

Aliment Pharmacol Ther. 2015 Mar;41(6):521-31.

7.

Self-reported need for psychotherapy predicts interferon-induced depression in hepatitis C: stratification for interferon-free treatment.

Staufer K, **Scherzer TM**, Miehsler W, Reichhold D, Kienbacher C, Ferenci-Förster D, Hagmann M, Ferenci P, Moser G.

Antivir Ther. 2015;20(5):501-6.

8.

Reply to: "DHEA and progesterone have a protective effect on ribavirin-induced hemolysis".

Eder E, **Scherzer TM**, Hofer H, Ferenci P.

J Hepatol. 2014 Apr;60(4):898-9. doi: 10.1016/j.jhep.2013.12.028.

9.

Polymorphisms of interferon- λ 4 and IL28B - effects on treatment response to interferon/ribavirin in patients with chronic hepatitis C.

Stättermayer AF, Strassl R, Maieron A, Rutter K, Stauber R, Strasser M, Beinhardt S, Datz C, **Scherzer TM**, Steindl-Munda P, Gschwantler M, Trauner M, Hofer H, Ferenci P.

Aliment Pharmacol Ther. 2014 Jan;39(1):104-11.

10.

Role of FDFT1 polymorphism for fibrosis progression in patients with chronic hepatitis C.

Stättermayer AF, Rutter K, Beinhardt S, Wrba F, **Scherzer TM**, Strasser M, Hofer H, Steindl-Munda P, Trauner M, Ferenci P.

Liver Int. 2014 Mar;34(3):388-95.

11.

Effect of gender and ITPA polymorphisms on ribavirin-induced anemia in chronic hepatitis C patients.

Scherzer TM, Stättermayer AF, Stauber R, Maieron A, Strasser M, Laferl H, Schwarzer R, Datz C, Rutter K, Beinhardt S, Steindl-Munda P, Hofer H, Ferenci P.

J Hepatol. 2013 Nov;59(5):964-71.

12.

Durability of SVR in chronic hepatitis C patients treated with peginterferon- α 2a/ribavirin in combination with a direct-acting anti-viral.

Rutter K, Hofer H, Beinhardt S, Dulic M, Gschwantler M, Maieron A, Laferl H, Stättermayer AF, **Scherzer TM**, Strassl R, Holzmann H, Steindl-Munda P, Ferenci P.

Aliment Pharmacol Ther. 2013 Jul;38(2):118-23.

13.

Long-term follow-up of hepatitis B e antigen-negative patients treated with peginterferon α -2a: progressive decrease in hepatitis B surface antigen in responders.

Rijckborst V, Ferenci P, Akdogan M, Pinarbasi B, ter Borg MJ, Simon K, Flisiak R, Akarca US, Raptopoulou-Gigi M, Verhey E, van Vuuren AJ, Boucher CA, Hansen BE, Janssen HL; PARC Study Group..

Eur J Gastroenterol Hepatol. 2012 Sep;24(9):1012-9.

14.

Association of the IL28B genotype with insulin resistance in patients with chronic hepatitis C.

Stättermayer AF, Rutter K, Beinhardt S, **Scherzer TM**, Stadlmayr A, Hofer H, Wrba F, Steindl-Munda P, Krebs M, Datz C, Trauner M, Ferenci P.

J Hepatol. 2012 Sep;57(3):492-8.

15.

The risk of infections in HIV-HCV coinfecting patients during antiviral therapy with pegIFN+RBV.

Payer BA, Reiberger T, Breitenacker F, Aichelburg MC, Schuster C, Heil PM, **Scherzer TM**, Ferenci P, Rieger A, Peck-Radosavljevic M; Vienna HIV & Liver Study Group..

J Infect. 2012 Aug;65(2):142-9.

16.

Serum level of IP-10 increases predictive value of IL28B polymorphisms for spontaneous clearance of acute HCV infection.

Beinhardt S, Aberle JH, Strasser M, Dulic-Lakovic E, Maieron A, Kreil A, Rutter K, Staettermayer AF, Datz C, **Scherzer TM**, Strassl R, Bischof M, Stauber R, Bodlaj G, Laferl H, Holzmann H, Steindl-Munda P, Ferenci P, Hofer H.

Gastroenterology. 2012 Jan;142(1):78-85.e2.

17.

Drolz A, Saxa R, **Scherzer T**, Fuhrmann V.

Liver Int. 2011 Sep;31 Suppl 3:19-23.

18.

Intravenous silibinin as 'rescue treatment' for on-treatment non-responders to pegylated interferon/ribavirin combination therapy.

Rutter K, **Scherzer TM**, Beinhardt S, Kerschner H, Stättermayer AF, Hofer H, Popow-Kraupp T, Steindl-Munda P, Ferenci P.

Antivir Ther. 2011;16(8):1327-33.

19.

Impact of IL28B on treatment outcome in hepatitis C virus G1/4 patients receiving response-guided therapy with peginterferon alpha-2a (40KD)/ribavirin.

Scherzer TM, Stättermayer AF, Strasser M, Laferl H, Maieron A, Stauber R, Datz C, Dulic-Lakovic E, Steindl-Munda P, Hofer H, Ferenci P.

Hepatology. 2011 Nov;54(5):1518-26.

20.

Treatment of chronic hepatitis C genotype 1 patients at an academic center in Europe involved in prospective, controlled trials: is there a selection bias?

Beinhardt S, Staettermayer AF, Rutter K, Maresch J, **Scherzer TM**, Steindl-Munda P, Hofer H, Ferenci P.

Hepatology. 2012 Jan;55(1):30-8.

21.

Shortening of treatment duration in patients with chronic hepatitis C genotype 2 and 3 - impact of ribavirin dose - a randomized multicentre trial.

Maieron A, Metz-Gercek S, **Scherzer TM**, Laferl H, Fischer G, Bischof M, Gschwantler M, Ferenci P.

BMC Res Notes. 2011 Jun 29;4:220.

22.

Development of ARDS after Excessive Kath Consumption: A Case Report.

Wewalka M, Drolz A, Staufer K, **Scherzer TM**, Fuhrmann V, Zauner C.

Case Rep Crit Care. 2011;2011:291934.

23.

Early virologic response and IL28B polymorphisms in patients with chronic hepatitis C genotype 3 treated with peginterferon alfa-2a and ribavirin.

Scherzer TM, Hofer H, Staettermayer AF, Rutter K, Beinhardt S, Steindl-Munda P, Kerschner H, Kessler HH, Ferenci P.

J Hepatol. 2011 May;54(5):866-71.

24.

Silibinin monotherapy prevents graft infection after orthotopic liver transplantation in a patient with chronic hepatitis C.

Beinhardt S, Rasoul-Rockenschaub S, **Scherzer TM**, Ferenci P.

J Hepatol. 2011 Mar;54(3):591-2; author reply 592-3.

25.

Impact of IL28B genotype on the early and sustained virologic response in treatment-naïve patients with chronic hepatitis C.

Stättermayer AF, Stauber R, Hofer H, Rutter K, Beinhardt S, **Scherzer TM**, Zinober K, Datz C, Maieron A, Dulic-Lakovic E, Kessler HH, Steindl-Munda P, Strasser M, Krall C, Ferenci P.

Clin Gastroenterol Hepatol. 2011 Apr;9(4):344-350.e2.

26.

Prevalence and clinical significance of GB virus type C/hepatitis G virus coinfection in patients with chronic hepatitis C undergoing antiviral therapy.

Hofer H, Aydin I, Neumueller-Guber S, Mueller C, **Scherzer TM**, Staufer K, Steindl-Munda P, Wrba F, Ferenci P.

J Viral Hepat. 2011 Jul;18(7):513-7.

27

A randomized trial of peginterferon alpha-2a with or without ribavirin for HBeAg-negative chronic hepatitis B.

Rijckborst V, ter Borg MJ, Cakaloglu Y, Ferenci P, Tabak F, Akdogan M, Simon K, Raptopoulou-Gigi M, Ormeci N, Zondervan PE, Verhey E, van Vuuren AJ, Hansen BE, Janssen HL; PARC Study Group..

Am J Gastroenterol. 2010 Aug;105(8):1762-9.

28.

Seminal fluid ribavirin level and functional semen parameters in patients with chronic hepatitis C on antiviral combination therapy.

Hofer H, Donnerer J, Sator K, Staufer K, **Scherzer TM**, Dejaco C, Sator M, Kessler H, Ferenci P.

J Hepatol. 2010 Jun;52(6):812-6.

29.

Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and 4 patients with slow virologic response.

Ferenci P, Laferl H, **Scherzer TM**, Maieron A, Hofer H, Stauber R, Gschwantler M, Brunner H, Wenisch C, Bischof M, Strasser M, Datz C, Vogel W, Löschenberger K, Steindl-Munda P; Austrian Hepatitis Study Group..

Gastroenterology. 2010 Feb;138(2):503-12, 512.e1.

30.

Plasmacytoid dendritic cells express TRAIL and induce CD4+ T-cell apoptosis in HIV-1 viremic patients.

Sary G, Klein I, Kohlhofer S, Koszik F, **Scherzer T**, Müllauer L, Quendler H, Kohrgruber N, Stingl G.

Blood. 2009 Oct 29;114(18):3854-63.

31.

Efficacy and safety of antiviral therapy in patients with Crohn's disease and chronic hepatitis C.

Scherzer TM, Staufer K, Novacek G, Steindl-Munda P, Schumacher S, Hofer H, Ferenci P, Vogelsang H.

Aliment Pharmacol Ther. 2008 Sep 15;28(6):742-8.

32.

Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy.

Ferenci P, **Scherzer TM**, Kerschner H, Rutter K, Beinhardt S, Hofer H, Schöniger-Hekele M, Holzmann H, Steindl-Munda P.

Gastroenterology. 2008 Nov;135(5):1561-7.

33.

Hepatocellular carcinoma in long-term sustained virological responders following antiviral combination therapy for chronic hepatitis C.

Scherzer TM, Reddy KR, Wrba F, Hofer H, Staufer K, Steindl-Munda P, Gangl A, Ferenci P.

J Viral Hepat. 2008 Sep;15(9):659-65.

34.

Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response.

Ferenci P, Laferl H, **Scherzer TM**, Gschwantler M, Maieron A, Brunner H, Stauber R, Bischof M, Bauer B, Datz C, Löschenberger K, Formann E, Staufer K, Steindl-Munda P; Austrian Hepatitis Study Group..

Gastroenterology. 2008 Aug;135(2):451-8.

35.

A randomized, prospective trial of ribavirin 400 mg/day versus 800 mg/day in combination with peginterferon alfa-2a in hepatitis C virus genotypes 2 and 3.

Ferenci P, Brunner H, Laferl H, **Scherzer TM**, Maieron A, Strasser M, Fischer G, Hofer H, Bischof M, Stauber R, Gschwantler M, Steindl-Munda P, Staufer K, Löschenberger K; Austrian Hepatitis Study Group..

Hepatology. 2008 Jun;47(6):1816-23.